SynCardia's Emperor TAH completes next-gen preclinical implant series
Picard Medical, parent company of SynCardia Systems, has completed a series of acute preclinical implant studies using the latest iteration of its Emperor Total Artificial Heart (TAH) platform, reporting stable haemodynamic support across all three procedures with no device-related intraoperative failures.
The studies were carried out at the University of Arizona and Banner University Medical Center in Tucson. The current iteration introduces an independent dual motor ventricular architecture that enables side-specific control of systemic and pulmonary circulation — an advance on the first-generation Emperor TAH, preclinical data for which were presented at the American College of Cardiology and the International Society for Heart & Lung Transplantation conferences earlier in 2026.
What the data showed
Across the three acute implant procedures, the Emperor TAH demonstrated what the company characterised as physiologically consistent autoregulatory behaviour. André Simon, Vice President of Clinical Affairs, described the animal study as generating "important data supporting continued preclinical and translational development activities." Matthew Schuster, Chief Operating Officer and inventor of the Emperor, said the independent ventricular architecture "operated as intended under study conditions" and that the results would support ongoing system optimisation.
The electromechanically actuated design is intended to build on the blood-contacting architecture and clinical record of SynCardia's existing approved device, the SynCardia Total Artificial Heart (STAH), while targeting a step-change in patient mobility. The long-term goal is a fully implantable system that removes the need for the external pneumatic driver currently required by the STAH. The Emperor TAH has not received FDA approval or clearance and remains in preclinical development.
Market context and competitive landscape
The total artificial heart segment is narrow but strategically significant. The STAH has accumulated more than 2,100 implants across 27 countries, making SynCardia the dominant commercial player in a market where regulatory barriers to entry are formidable and clinical experience compounds over years. The Emperor programme is designed to extend that incumbency by addressing the platform's most cited limitation: the tethering of patients to external pneumatic equipment, which restricts mobility and imposes significant quality-of-life constraints.
The broader mechanical circulatory support space is more crowded at the ventricular assist device (VAD) end, with Abbott's HeartMate 3 holding a strong position in left ventricular support. However, total artificial heart devices address biventricular failure — a distinct and underserved patient population for whom VADs are typically insufficient. If Picard Medical can advance the Emperor to a fully implantable configuration, it would represent a meaningful clinical differentiator in a segment with no near-term direct competitor at the same stage of development.
The company has not disclosed a timeline for IND filing or first-in-human studies. Regulatory precedent from the STAH approval pathway — spanning both the FDA and Health Canada — provides SynCardia with an institutional knowledge base that smaller entrants would struggle to replicate. Investors and clinicians will be watching for translational study designs, longer-duration chronic implant data, and an indication of when the programme might move toward a human feasibility study.
Chief executive Patrick Schnegelsberg framed the preclinical milestone in terms of the company's broader ambition: "The Emperor TAH is designed to build on decades of clinical experience from the SynCardia platform, with the goal of improving patient mobility and quality of life."